Efficacy and safety of nintedanib in japanese patients with progressive fibrosing interstitial lung diseases: subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 inbuild trial

HIGHLIGHTS

• who: Yoshikazu Inoue from the Japan JapanHamamatsu University School of Medicine, Second Division, Department of Internal Medicine, Shizuoka, Japan have published the research: Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial, in the Journal: (JOURNAL)
• what: The authors report the Japanese subgroup analysis of the INBUILD trial to evaluate the consistency of the efficacy and safety of ninte­ danib in Japanese patients with progressive fibrosing ILDs compared with the overall INBUILD trial.
• future: Unfortunately . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.